Nopporn Unnoppet, DO
Rheumatology · Alabaster, ALNPI 1033371323
Payments from drug & device makers
Across 508 payments — averaging $43.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$16K
- Amgen$1K
- AstraZeneca$1K
- Pfizer$920
- Novartis$538
- E.r. Squibb & Sons, L.L.C.$470
- plus $2K from 13 others
What the payments were for
- Consulting fees$8,39838%
- Travel & lodging$3,42415%
- Food & beverage$10,38547%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 204 | $16,065 |
| Amgen(2 entities) | 68 | $1,250 |
| AstraZeneca(2 entities) | 41 | $1,165 |
| Pfizer | 63 | $920 |
| Novartis | 21 | $538 |
| E.r. Squibb & Sons, L.L.C. | 26 | $470 |
| GSK | 23 | $426 |
| Johnson & Johnson | 11 | $323 |
| UCB, Inc. | 9 | $255 |
| Regeneron Healthcare Solutions, Inc. | 8 | $252 |
| Fresenius Kabi USA, LLC | 7 | $124 |
| Genentech USA, Inc. | 5 | $91 |
| Medexus Pharma, Inc. | 5 | $87 |
| Lilly USA, LLC | 6 | $85 |
| Sandoz | 4 | $78 |
| Radius Health, Inc. | 3 | $67 |
| Acella Pharmaceuticals, LLC | 2 | $31 |
| Aurinia Pharma U.S., Inc. | 1 | $23 |
| Currax Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,262 in reported general payments places this provider in the 75th percentile of 90 rheumatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 215 | $1,642,754 |
| RinvoqUpadacitinib | 100 | $669,942 |
| Enbrel MiniEtanercept | 34 | $301,457 |
| OrenciaAbatacept | 35 | $280,898 |
| Xeljanz XrTofacitinib Citrate | 34 | $215,466 |
| EnbrelEtanercept | 26 | $202,867 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 21 | $162,046 |
| Orencia ClickjectAbatacept | 14 | $132,122 |
| Yuflyma(Cf) Autoinject (2 Pck)Adalimumab-Aaty | 16 | $122,408 |
| ProliaDenosumab | 68 | $117,211 |
| Humira PenAdalimumab | 15 | $100,693 |
| OrenciaAbatacept/Maltose | 16 | $92,044 |
| Enbrel SureclickEtanercept | 12 | $84,783 |
| Taltz AutoinjectorIxekizumab | 12 | $81,254 |
| Hydroxychloroquine Sulfate | 1,329 | $63,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $16,065 | $669,942100 claims |
| E.r. Squibb & Sons, L.L.C.Orencia, Orencia | $470 | $372,94251 claims |
| AmgenEnbrel, Prolia | $1,250 | $320,07894 claims |
| Lilly USA, LLCForteo | $85 | $56,40312 claims |
| Radius Health, Inc.Tymlos | $67 | $37,52614 claims |
| Medexus Pharma, Inc.Rasuvo | $87 | $16,43423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 90 rheumatology providers in Alabama.
Other rheumatology in Alabaster
- Jeffrey CurtisBirmingham$17.6M
- Kenneth SaagBirmingham$8.2M
- Vishala ChindaloreAnniston$3.5M
- Anthony TurkiewiczMountain Brk$2.5M
- Harry SchroederBirmingham$938K
- Jose Rubio MosqueraBirmingham$823K
- David McLainBirmingham$588K
- William ShergyHuntsville$453K
- Ray McLaughinTuscaloosa$332K
- Edmund LacourDothan$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.